Intravenous type II glycoengineered anti-CD20 monoclonal antibody that induces direct B-cell death and enhances ADCC/ADCP.
Glycoengineered type II humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on malignant B cells and mediates cytotoxicity via enhanced Fc-gamma RIII–dependent ADCC and ADCP, and by inducing direct, largely caspase-independent apoptosis, leading to B-cell depletion.
Binds CD20 on B cells, inducing direct (largely caspase-independent) apoptosis and recruiting Fc receptor–bearing effector cells to mediate ADCC and ADCP, leading to CD20+ cell killing.
Allogeneic natural killer cells genetically engineered to express a chimeric antigen receptor targeting CD19; CAR engagement activates NK cytotoxic pathways to kill CD19-positive B-cell malignancies.
Allogeneic natural killer cells engineered to express an anti-CD19 chimeric antigen receptor bind CD19 on B cells, activating NK cytotoxic pathways (perforin/granzyme release and cytokine-mediated killing) to selectively lyse CD19-positive malignant cells; some designs include inhibitory signaling to reduce off-tumor effects.
Anti-CD19 CAR NK cells bind CD19 on target cells and trigger NK effector functions, causing perforin/granzyme-mediated cytolysis (and death receptor pathways) of CD19+ cells.
Intravenous bispecific monoclonal antibody (T‑cell engager) that binds BCMA on plasma cells and CD3 on T cells, redirecting T‑cell cytotoxicity to deplete pathogenic plasma cells and reduce amyloidogenic light‑chain production in systemic AL amyloidosis. Also known as REGN5458; brand name Lynozyfic.
Bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells, redirecting T‑cell cytotoxicity to deplete BCMA+ plasma cells and reduce amyloidogenic light‑chain production in AL amyloidosis.
The bispecific antibody binds BCMA on target cells and CD3 on T cells, creating an immune synapse that redirects T-cell cytotoxicity (perforin/granzyme-mediated apoptosis) to kill BCMA+ cells.
Subcutaneous anti-CD38 IgG1 monoclonal antibody targeting CD38 on plasma cells; mediates ADCC, CDC, ADCP, and apoptosis, and depletes CD38+ immunosuppressive cells (Tregs, Bregs, MDSCs).
Human IgG1 monoclonal antibody targeting CD38 that binds CD38 on myeloma/plasma cells and CD38+ immunosuppressive cells, inducing direct apoptosis and Fc-mediated cytotoxicity (ADCC, CDC) and phagocytosis (ADCP), leading to depletion of CD38-expressing cells and enhanced antitumor immunity.
Daratumumab binds CD38 on target cells and induces direct apoptosis and Fc/complement-dependent killing (NK-cell ADCC, macrophage ADCP, and CDC), depleting CD38+ cells.
A STEAP1-targeted antibody–drug conjugate (ADC) that binds STEAP1 on tumor cells and, upon internalization, releases a cytotoxic payload to selectively kill STEAP1-expressing cancer cells.
A STEAP1-targeted antibody-drug conjugate that binds STEAP1 on tumor cells, is internalized, and releases an intracellular cytotoxic payload to selectively kill STEAP1-expressing cancer cells.
The ADC binds STEAP1 on tumor cells, is internalized, and releases an intracellular cytotoxic payload that kills STEAP1-expressing cells (e.g., via microtubule disruption or DNA damage).